Prostate Cancer Discovered in 40 Percent of Men Who Test Negative for the Disease
Posted on: Monday, 15 December 2008, 15:49 CST
Researchers used an advanced biopsy technique called stereotactic transperineal prostate biopsy (STPB). This was performed on patients with persistent elevated prostate specific antigen (PSA) levels who previously had at least one negative office biopsy. All patients had received transrectal prostate biopsies (TRPB), administered by a urologist.
"Men who have negative transrectal biopsies and continue to have elevated
PSA levels should consider STPB because 40% will harbor malignancy," says
STPB is performed by taking a median of 40 samples of the prostate through the perineum while the patient is under general anesthesia. Performed as an outpatient procedure, it allows more comprehensive sampling, compared to the transrectal method, which takes fewer samples through the rectum. In addition, by taking more samples during STPB, the exact location of the cancer can be pinpointed.
Between
One in six men in the U.S. will be diagnosed with prostate cancer, the most common form of cancer among men. For those with elevated or rising PSA levels, this is a sign that further testing should be administered to rule out prostate cancer.
The Prostate Cancer Foundation of
SOURCE The Prostate Cancer Foundation of
Source: PR Newswire
Related Articles
- Philadelphia Cancer Patients to Benefit from Expansion of the American Cancer Society Patient Navigator Program
- ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinson's Disease Research to Develop Tolls for Imaging Alpha-Synuclein Aggregation in Living Parkinson's Brain
- Two Scientists Honored with MetLife Foundation Awards for Medical Research in Alzheimer's Disease
- Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
- Aradigm Announces Data Showing No Occurrence of Primary Lung Cancer in Patients Treated With AERx(R) Insulin Diabetes Management System (iDMS)
- The Tug McGraw Foundation and Accelerate Brain Cancer Cure Collaborate to Fund Innovative UCSF Brain Tumor Research
- Delaware Cancer Patients Among Nation's First to Benefit From Expansion of the American Cancer Society's 'Patient Navigator Program'
- Valeant Pharmaceuticals Announces Availability of Complimentary ``Managing Chemotherapy Side Effects For Dummies'' Cancer Chemotherapy Resource; Special Edition ``For Dummies''(R) Book Now Available for Cancer Chemotherapy Patients and Caregivers
- Research Into a Protein for Treatment of Cancer Brings Prestigious Susan G. Komen Foundation Award
- Powell Has Cancerous Prostate Removed
User Comments (0)

RSS Feeds